Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03210883 · ClinicalTrials.gov registry record
Global Electrical Heterogeneity and Clinical Outcomes
A clinical trial of Heart Failure and Implantable Defibrillator User, sponsored by Larisa Tereshchenko.
- Completed
- Registry status
- 3,471
- Enrollment target
- 6
- Study locations
NCT03210883: Completed study of Heart Failure and Implantable Defibrillator User, sponsored by Larisa Tereshchenko.
NCT03210883 is a study of Heart Failure and Implantable Defibrillator User that has completed, run by Larisa Tereshchenko. The registered enrollment target is 3,471 participants, above the 2,040-participant average among 397 other Heart Failure trials with a reported enrollment target (70% higher). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03210883, a study of Heart Failure and Implantable Defibrillator User, has completed, sponsored by Larisa Tereshchenko.
- COMPLETED
- Registry status
- 3,471 participants
- Enrollment target
- 6
- Study locations
Study Summary
This retrospective multicenter cohort will validate an independent association of electrocardiographic (ECG) global electrical heterogeneity (GEH) measures with sustained ventricular tachyarrhythmias and appropriate ICD therapies in systolic heart failure patients with primary prevention ICD, and will validate and re-calibrate GEH ECG risk score for prediction of sustained ventricular tachyarrhythmias and appropriate ICD therapies in systolic heart failure patients with primary prevention ICD.
Primary Outcome
Sustained ventricular tachyarrhythmia event with appropriate ICD therapy (either antitachycardia pacing or shock)
Conditions Studied
Study Locations (6)
California
- Cedars-Sinai Medical Center - Los Angeles
- Stanford University - Stanford
Oregon
- Oregon Health and Science University - Portland
- Veteran Administration Portland Healthcare System - Portland
Colorado
- University of Colorado - Aurora
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,471 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2021-07-05 |
What the finished NCT03210883 record still lists
NCT03210883 is an observational study that tracks outcomes without assigning an intervention. Its 3,471 participants enrollment target places it among the larger protocols in the corpus, above the 2,040-participant average among 397 other Heart Failure trials with a reported enrollment target (70% higher).
The record links to 3 conditions, with Heart Failure appearing as the primary indexed condition, and to 0 interventions.
NCT03210883 lists 6 locations in 4 states (California, Oregon, Colorado).
Frequently Asked Questions
What is clinical trial NCT03210883 about?
NCT03210883 is a clinical study titled "Global Electrical Heterogeneity and Clinical Outcomes". This retrospective multicenter cohort will validate an independent association of electrocardiographic (ECG) global electrical heterogeneity (GEH) measures with sustained ventricular tachyarrhythmias and appropriate ICD therapies in systolic heart failure patients with primary prevention ICD, and wi...
What is the current status of trial NCT03210883?
This trial is currently completed. The enrollment target is 3,471 participants. The study started on 2017-07-01. Estimated completion is 2021-07-05.
What conditions does trial NCT03210883 study?
This clinical trial studies the following conditions: Heart Failure, Implantable Defibrillator User, Ventricular Arrythmia.
Who is sponsoring clinical trial NCT03210883?
This trial is sponsored by Larisa Tereshchenko, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03210883 being conducted?
This trial has 6 study locations across California, Colorado, Massachusetts, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03210883's enrollment target sits among peer trials
3,471 33rd of 397 higher than 365 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
RECRUITING
-
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- NCT01612949 · 3,500 participants
Facial Analysis to Classify Difficult Intubation
- NCT02398786 · 3,500 participants
Myotonic Dystrophy Family Registry
- NCT03486873 · 3,500 participants · Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI